Recombinant Human Claudin 4 Protein-VLP, Active
Beta LifeScience
SKU/CAT #: BLK-00307P-100UG
The purity of Human Claudin 4 VLP is greater than 95% as determined by SEC-HPLC.
Recombinant Human Claudin 4 Protein-VLP, Active
Beta LifeScience
SKU/CAT #: BLK-00307P-100UG
Collections: Recombinant proteins, Virus-like particle (vlp) proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human Claudin 4 Protein-VLP is expressed from HEK293.It contains Met1-Val209. |
Purity | > 95% as determined by HPLC |
Accession | O14493 |
Target Symbol | Claudin 4 |
Species | Human |
Expression System | HEK293 |
Expression Range | Met1-Val209 |
Mol. Weight | The target protein has a predicted MW of 23.31 kDa. |
Form | Liquid |
Formulation | Supplied as 0.22um filtered solution in PBS, 300mM L-Arginine (pH 7.4). |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human Claudin 4 VLP at 1ug/ml (100ul/well) on the plate. Dose response curve for Anti-Claudin 4 Antibody, hFc Tag with the EC50 of 18.4ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping | Shipped with dry ice. |
Gene Background | Claudin-4 (CLDN4) is a key component of tight junctions (TJs) in epithelial cells. CLDN4 is overexpressed in many epithelial malignancies and correlates with cancer progression. Changes in CLDN4 expression have been associated with epigenetic factors (such as hypomethylation of promoter DNA), inflammation associated with infection and cytokines, and growth factor signaling. CLDN4 helps to maintain the tumor microenvironment by forming TJs and acts as a barrier to the entry of anticancer drugs into tumors. |